Regeneron Cholesterol-Lowering Drug Banned From U.S. Market
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
A federal judge has banned the sale of Regeneron Pharmaceuticals' (REGN) - Get Report cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen (AMGN) - Get Report and its competing drug Repatha in a long-running patent lawsuit. Regeneron and Sanofi (SNY) - Get Report intend to appeal both the original patent infringement decision and the judge's injunction against Praluent.
This article was written by a staff member of TheStreet.
